Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 19, Issue 2, 2012, Pages 171-178

  Shimizu, Koichi ^a   Kotera, Yoshihito ^a   Aruga, Atsushi ^a   Takeshita, Nobuhiro ^a   Takasaki, Ken ^a   Yamamoto, Masakazu ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Adjuvant therapy; Cancer vaccine; Dendritic cell; Immunotherapy; Intrahepatic cholangiocarcinoma; Recurrence

Indexed keywords

DENDRITIC CELL VACCINE;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT SURGERY; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SAFETY; EX VIVO STUDY; FEMALE; HUMAN; INJECTION SITE REACTION; LYMPHOCYTE TRANSFER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE CARE; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TUMOR VOLUME;

ADOPTIVE TRANSFER; AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CANCER VACCINES; CHOLANGIOCARCINOMA; DENDRITIC CELLS; FEMALE; HUMANS; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PROSPECTIVE STUDIES; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84857063810     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1007/s00534-011-0437-y     Document Type: Article

References (19)

1. Yamamoto M, Ariizumi S. Intrahepatic recurrence after surgery in patients with intrahepatic cholangiocarcinoma. J Gastoenterol. 2006;41(9):925-6. (Pubitemid 44594238)
2. Yamamoto M, Takasaki K, Otsubo T, Katsuragawa H, Katagiri S. Recurrence after surgical resection of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2001;8(2):154-7. (Pubitemid 33690530)
3. Kotera Y, Shimizu K, Mule JJ. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res. 2001;61(22):8105-9. (Pubitemid 33091598)
4. Shimizu K, Thomas EK, Giedlin M, Mule JJ. Enhancement of tumor-lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res. 2001;61(6): 2618-24. (Pubitemid 32685847)
5. Engell-Noerregaard L, Hansen TH, Andersen MH, Straten PT, Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother. 2009;58(1):1-14.
6. Shimizu K, Tanigawa K, Takeshita N, Fujisawa T, Takasaki K, Yamamoto M, Aruga A. A Phase I/II trial of combination therapy of tumor lysate-pulsed dendritic cells and adoptive transfer of anti-CD3 activated T cells (ATVAC) in patients with advanced gastrointestinal (GI) cancers. J Immunother. 2008;31(9):926.
7. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, Sciot R, Wilms G, Demaerel P, Warmuth- Metz M, Soerensen N, Wolf JEA, Wagner S, Kaempgen E, Van Gool SW. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res. 2008;14(10):3098-104.
8. Rutlowski S, De Vleeschouwer S, Kaempgen E, Wolf JEA, Kuhl J, Demaerel P, Warmuth-Metz M, Flamen P, Van Calenbergh F, Plets C, Sorensen N, Opitz A, Van Gool SW. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer. 2004;91(9):1656-62. (Pubitemid 39546137)
9. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial. Lancet. 2000;356(9232):802-7.
10. Chang AE, Aruga A, Cameron MJ, Sondak VK, Normolle DP, Fox BA, Shu S. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol. 1997;15(2):796-807. (Pubitemid 27074251)
11. Matsuda A, Kuno A, Kawamoto T, Matsuzaki H, Irimura T, Ikehara Y, Zen Y, Nakanuma Y, Yamamoto M, Ohkohchi N, Shoda J, Hirabayashi J, Narimatsu H. Wisteria floribunda agglutinin-positive mucin 1 is a sensitive biliary marker for human cholangiocarcinoma. Hepatology. 2010;52(1):174-82.
12. Matsumura N, Yamamoto M, Aruga A, Takasaki K, Nakano M. Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma. Cancer. 2001;94(6):1770-6. (Pubitemid 34241116)
13. Lepisto AJ, Moser AJ, Zeh H, Lee K, Bartlett D, McKolanis JR, Geller BA, Schmotzer A, Potter DP, Whiteside T, Finn OJ, Ramanathan RK. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther. 2008;6(B):955-64.
14. Higuchi R, Yamamoto M, Hatori T, Hatori T, Shimizu K, Imai K, Takasaki K. Intrahepatic cholangiocarcinoma with lymph node metastasis successfully treated by immunotherapy with CD3- activated T cells and dendritic cells after surgery: report of a case. Surg Today. 2006;36(6):559-62. (Pubitemid 43781486)
15. Miyazawa M, Ohsawa R, Tsunoda T, Hirono S, Kawai M, Tani M, Nakamura Y, Yamaue H. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci. 2010;101(2):422-9.
16. Koike N, Pilon-Thomas S, Mule JJ. Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cellbased vaccination results in rejection of established melanoma. J Immunother. 2008;31(4):402-12. (Pubitemid 351595163)
17. Matsushita N, Pilon-Thomas SA, Martin LM, Riker AI. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods. 2008;333(1-2):167-79.
18. Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiechi D, Lyerly DH, Clay TM. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood. 2008;112(3):610-8.
19. Fukuma D, Matsuyoshi H, Hirta S, Kurisaki A, Motomura Y, Yoshitake Y, Shinohara M, Nishimura Y, Senju S. Cancer prevention with semi-allogeneic ES cell-derived dendritic cells. Biochem Biophys Res Commun. 2005;335(1):5-13. (Pubitemid 41350757)